Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors

This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before radiation can improve outcomes for people with advanced nasopharyngeal cancer. Participants receive three cycles of toripalimab plus gemcitabine and cisplatin, then undergo standard radiation. The main goal is to see how many patients achieve a complete response—meaning their tumors disappear entirely on scans. The study enrolls adults aged 18 to 65 with a specific type of nasopharyngeal cancer that has spread locally but not to distant organs.